Loading...
XASE
CPHI
Market cap2mUSD
Jul 09, Last price  
0.64USD
1D
-5.88%
1Q
-0.88%
Jan 2017
-99.51%
IPO
-99.84%
Name

China Pharma Holdings Inc

Chart & Performance

D1W1MN
XASE:CPHI chart
P/E
P/S
0.49
EPS
Div Yield, %
Shrs. gr., 5y
-1.44%
Rev. gr., 5y
-17.53%
Revenues
4m
-8.49%
21,843,26233,186,32450,968,66061,696,62074,388,18081,166,73954,507,04932,806,67722,133,86620,351,63015,570,51413,212,31412,330,68710,923,93610,866,4499,641,9258,104,0927,011,2994,528,9294,144,268
Net income
-3m
L-32.70%
8,587,08612,819,53317,833,65020,233,04923,414,34719,269,6424,617,659-20,008,049-26,047,375-15,405,518-9,182,624-19,277,565-10,750,167-20,702,044-2,866,777-3,399,476-3,972,841-3,078,818-4,736,365-3,187,556
CFO
148k
P
-1,736,3332,801,8986,543,26010,668,9267,785,4875,237,3243,643,8208,595,8154,572,3723,350,0602,895,708841,2161,256,992608,312-42,260-249,838-409,545-699,686-466,362148,261

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

China Pharma Holdings, Inc. (CPHI) specializes in the development, manufacturing, and marketing of both generic and branded pharmaceutical as well as biochemical products. The company primarily caters to hospitals and independent retailers throughout mainland China. Its comprehensive product portfolio encompasses diverse formulations, including powdered and liquid injectables, oral tablets, capsules, and cephalosporin-based oral solutions. CPHI's extensive range of medical solutions targets various health conditions. For neurological and cognitive health, it offers Cerebroprotein Hydrolysate injections to address memory decline and attention deficits, and Gastrodin injections for symptoms such as fatigue, lack of concentration, sleep disturbances, and traumatic brain syndromes. Cardiovascular and cerebrovascular treatments include Propylgallate and Ozagrel Sodium for conditions like cerebral thrombosis, coronary heart disease, and post-surgical recovery, as well as Alginic Sodium Diester injections targeting ischemic heart disease, cerebrovascular ailments, and hyperlipoproteinemia. Additionally, CPHI provides Bumetanide injections for edema management and Candesartan for hypertension. The company also produces a variety of anti-infective medications. These feature Roxithromycin dispersible tablets for throat infections (pharyngitis and tonsillitis), and Cefaclor dispersible tablets effective against conditions such as otitis media, lower respiratory tract infections, urinary tract infections, and skin/soft tissue infections. Other anti-infectives include Cefalexin capsules for acute tonsillitis, Andrographolide for sore throats stemming from upper respiratory tract infections, and Clarithromycin available in both granule and capsule forms. For pain and cold relief, CPHI offers sustained-release tablets containing Naproxen Sodium and Pseudoephedrine Hydrochloride. Furthermore, CPHI manufactures treatments for digestive disorders, including Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeprazole. The product lineup extends to Vitamin B6 injections, Granisetron Hydrochloride injections for alleviating nausea and vomiting induced by cancer therapies (radiotherapy and chemotherapy), and dietary supplements like Noni Enzyme. Complementing its medical offerings, the company also provides health-related products such as sanitizers and protective masks. The company distributes its offerings via a network of third-party distributors, augmented by its own 16 sales offices and a team of around 1,000 sales professionals. Established in 1993, China Pharma Holdings, Inc. maintains its headquarters in Haikou, located in the People's Republic of China.
IPO date
Feb 15, 2000
Employees
234
Domiciled in
CN
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT